However, more tumor reduction in the mice treated with an Akti-inhibited mixture of CD4 + CD19CAR and CD8 + CD19 CAR T cells indicates the minor impact of Akti-treated Tregs on the overall therapeutic effects. The gene discussed is CD4; the disease is neoplasm.